


What is claimed is:

1. A compound of Formula (I):



or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein:

5 X is independently CH₂O or OCH₂;

L₁ is independently a hydrocarbon linker substituted with 0-2 R^C, a hydrocarbon-heteroatom linker substituted with 0-2 R^C, or -(O)₀₋₁-(CH₂)₁₋₃-(C₃₋₄ cycloalkyl substituted with 0-2 R^C)-(CH₂)₀₋₂-; wherein said hydrocarbon linker has one to six carbon atoms and may be straight or branched, saturated or unsaturated; and said hydrocarbon-heteroatom linker has one to four carbon atoms and one group selected from O, CO, S(O)_p, NH, N(C₁₋₄ alkyl), CONH, NHCO and NHCO₂;

10 R¹ is independently selected from: C₆₋₁₀ carbocycle and a 5- to 10-membered heterocycle comprising carbon atoms and 1-4 heteroatoms selected from N, NR^b, O, and S(O)_p; wherein said carbocycle and heterocycle are substituted with 0-4 R³ and 0-1 R⁴;

R² independently selected from: OH, CO₂H, -CONH(C₁₋₄ alkyl), -CONHOH, -CONHSO₂R^e, and -CONH-(CH₂)₀₋₃-(5-membered heteroaryl comprising carbon atoms and 1-4 heteroatoms selected from N, NR^b, O, and S(O)_p);

20 R³, at each occurrence, is independently selected from: halogen, C₁₋₆ alkyl, C₁₋₄ alkoxy, C₁₋₄ alkylthio, C₁₋₄ haloalkyl, C₁₋₆ haloalkoxy, C₁₋₄ haloalkylthio, and NO₂;

R⁴ is independently -L₂-R⁵;

L₂ is independently selected from: a bond, O, S, CH₂, C(=O), and -OSO₂;

25 R⁵ is independently selected from: C₁₋₆ alkyl, C₂₋₆ alkenyl, C₁₋₆ haloalkyl, -(CH₂)_n-C₃₋₆ carbocycle and a 5- to 6-membered heterocycle comprising carbon atoms

and 1-4 heteroatoms selected from N, NR^b, O, and S(O)_p; wherein each ring moiety is substituted with 0-4 R^a;

R^a, at each occurrence, is independently selected from: OH, CN, halogen, C₁₋₄ alkyl substituted with 0-1 OH, C₁₋₄ alkoxy, and C₁₋₄ haloalkyl;

5 R^b, at each occurrence, is independently selected from: H, C₁₋₄ alkyl, and -(CH₂)₀₋₂-(phenyl substituted with 0-3 R^d);

R^c, at each occurrence, is independently selected from: halogen, OH, C₁₋₄ alkyl, C₁₋₄ haloalkyl, and C₁₋₄ alkoxy;

10 R^d, at each occurrence, is independently selected from: halogen, C₁₋₄ alkyl, C₁₋₄ alkoxy, and C₁₋₄ haloalkyl;

R^e is independently selected from: C₁₋₄ alkyl and phenyl;

p is, independently at each occurrence, selected from 0, 1, and 2; and

n is, independently at each occurrence, selected from 0, 1, and 2.

15 2. A compound according to claim 1, wherein:


L₁ is independently a hydrocarbon linker substituted with 0-1 R^c, a hydrocarbon-heteroatom linker substituted with 0-1 R^c, or -(O)₀₋₁-(CH₂)₁₋₃-(C₃₋₄ cycloalkyl substituted with 0-1 R^c)-(CH₂)₀₋₁-; wherein said hydrocarbon linker has one to six carbon atoms and may be straight or branched, 20 saturated or unsaturated; and said hydrocarbon-heteroatom linker has one to four carbon atoms and one group selected from O, CO, S(O)_p, CONH, and NHCO₂;

R¹ is independently selected from: phenyl, indanyl, naphthyl, and a 5- to 6-membered heterocycle comprising carbon atoms and 1-4 heteroatoms selected from N, NR^b, O, and S(O)_p; wherein each ring moiety substituted with 0-4 R³ and 0-1 R⁴;

25 L₂ is independently selected from: a bond, O, S, CH₂, and -OSO₂; and

R⁵ is independently selected from: C₁₋₆ alkyl, C₂₋₆ alkenyl, C₁₋₄ haloalkyl, tetrahydropyranyl, -(CH₂)_n-(C₃₋₆ carbocycle substituted with 0-2 R^a), and pyridyl substituted with 0-1 R^a.

3. A compound according to claim 1 or claim 2, wherein the compound is of Formula (II):



5 or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein:

X is independently CH_2O or OCH_2 ;

L_1 is independently a hydrocarbon linker substituted with 0-1 OH, a hydrocarbon-heteroatom linker or $-(\text{O})_{0-1}-(\text{CH}_2)_{1-3}-(\text{cyclopropyl})-(\text{CH}_2)_{0-1}-$; wherein said hydrocarbon linker has one to five carbon atoms and may be straight or branched, saturated or unsaturated; and said hydrocarbon-heteroatom linker has one to five carbon atoms and may be straight or branched, and has one to three carbon atoms and one group selected from O, CONH and NHCO_2 ;

R^3 , at each occurrence, is independently selected from: halogen, CF_3 , OCF_3 , SCF_3 , NO_2 , C_{1-4} alkyl, C_{1-4} alkoxy, and C_{1-4} alkylthio;

15 R^4 is independently $-\text{L}_2-\text{R}^5$;



L_2 is independently a bond, O or S;

R^5 is independently selected from: $-(\text{CH}_2)_{0-1}-\text{C}_{4-6}$ cycloalkyl, C_{5-6} cycloalkenyl, tetrahydropyranyl, pyridyl substituted with 0-2 R^a , and $-(\text{CH}_2)_n-(\text{phenyl substituted with 0-2 } \text{R}^a)$; and

20 R^a , at each occurrence, is independently selected from: OH, CN, halogen, C_{1-4} alkyl substituted with 0-1 OH, and C_{1-4} alkoxy.


4. A compound according to any one of claims 1 to 3, wherein:

L_1 is independently selected from: $(CH_2)_{3-4}$, $CH_2CH_2OCH_2$, $CH_2OCH_2CH_2$, $CH_2CH_2CH_2OCH_2$, $CH_2CH_2CH=CH$, $CH_2CH=CHCH_2$, $CH_2CONHCH_2$,

$CH_2NHCO_2CH_2$, , , and ; and

R^4 is independently selected from: cyclopentenyl, -O- CH_2 -cyclobutyl,
 5 -O- $(CH_2)_{0-1}$ -cyclohexyl, -O-tetrahydropyranyl, -O-pyridyl, and
 - L_3 -(CH_2) $_{0-1}$ -(phenyl substituted with 0-2 R^a).



5. A compound according to any one of claims 1 to 4, wherein the compound is of Formula (III):



10 or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein:

X is independently CH_2O or OCH_2 ;

L_1 is independently selected from: $(CH_2)_{3-4}$, $CH_2CH_2OCH_2$, $CH_2OCH_2CH_2$, $CH_2CH_2CH_2OCH_2$, $CH_2CH_2CH=CH$, $CH_2CH=CHCH_2$, $CH_2CONHCH_2$,

15 $CH_2NHCO_2CH_2$, , , and ;


L_2 is independently O or S;

R^3 , at each occurrence, is independently halogen or C_{1-4} alkoxy; and

R^a , at each occurrence, is independently selected from: CN, halogen, C_{1-4} alkyl, and C_{1-4} alkoxy.

20

6. A compound according to any one of claims 1 to 5, wherein:

L_1 is independently selected from: $(CH_2)_4$, $CH_2CH_2OCH_2$, $CH_2OCH_2CH_2$,
 $CH_2CH_2CH_2OCH_2$, $CH_2CH_2CH=CH$, $CH_2CH=CHCH_2$, , and
; and

L_2 is O.

5

7. A compound according to claim 1, wherein the compound is selected from the following, or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof:

- 10 3-(1-(3-phenoxyphenyl)-2-oxabicyclo[2.2.2]octan-4-yl)propanoic acid;
 3-(1-(3-phenoxyphenyl)-2-oxabicyclo[2.2.2]octan-4-yl)propanoic acid;
 5-(1-(3-methoxyphenyl)-2-oxabicyclo[2.2.2]octan-4-yl)pentanoic acid;
 5-(1-(2-methyl-4-phenylthiazol-5-yl)-2-oxabicyclo[2.2.2]octan-4-yl)pentanoic
 acid;
 3-((1-(3-phenoxyphenyl)-2-oxabicyclo[2.2.2]octan-4-yl)methoxy)propanoic acid;
 15 2-(2-(1-(3-phenoxyphenyl)-2-oxabicyclo[2.2.2]octan-4-yl)ethoxy)acetic acid;
 2-(2-(1-(3-isopropoxyphenyl)-2-oxabicyclo[2.2.2]octan-4-yl)ethoxy)acetic acid;
 2-(2-(1-(3-(cyclohexyloxy)phenyl)-2-oxabicyclo[2.2.2]octan-4-yl)ethoxy)acetic
 acid;
 2-(2-(1-(3-isobutoxyphenyl)-2-oxabicyclo[2.2.2]octan-4-yl)ethoxy)acetic acid;
 20 5-(1-(3-(tetrahydro-2H-pyran-2-yloxy)phenyl)-2-oxabicyclo[2.2.2]octan-4-
 yl)pentanoic acid;
 (E)-5-(1-(3-phenoxyphenyl)-2-oxabicyclo[2.2.2]octan-4-yl)pent-2-enoic acid;
 2-(3-(1-(3-phenoxyphenyl)-2-oxabicyclo[2.2.2]octan-4-yl)propoxy)acetic acid;
trans-2-(2-(1-(3-phenoxyphenyl)-2-oxabicyclo[2.2.2]octan-4-
 25 yl)ethyl)cyclopropanecarboxylic acid;
 (1S,2S)-2-(2-(1-(3-phenoxyphenyl)-2-oxabicyclo[2.2.2]octan-4-
 yl)ethyl)cyclopropanecarboxylic acid;

- (1*R*,2*R*)-2-(2-(1-(3-phenoxyphenyl)-2-oxabicyclo[2.2.2]octan-4-yl)ethyl)cyclopropanecarboxylic acid;
- 2-(2-((1-(3-phenoxyphenyl)-2-oxabicyclo[2.2.2]octan-4-yl)methyl)cyclopropyl)acetic acid (*trans*);
- 5 2-((1*R*,2*R*)-2-((1-(3-phenoxyphenyl)-2-oxabicyclo[2.2.2]octan-4-yl)methyl)cyclopropyl)acetic acid;
- 2-((1*S*,2*S*)-2-((1-(3-phenoxyphenyl)-2-oxabicyclo[2.2.2]octan-4-yl)methyl)cyclopropyl)acetic acid;
- 2-(2-(1-(3-(2-methylallyloxy)phenyl)-2-oxabicyclo[2.2.2]octan-4-yl)ethoxy)acetic acid;
- 10 acid;
- 2-(2-(1-(3-(2-methylprop-1-enyloxy)phenyl)-2-oxabicyclo[2.2.2]octan-4-yl)ethoxy)acetic acid;
- 2-(2-(1-(3-(pyridin-3-yloxy)phenyl)-2-oxabicyclo[2.2.2]octan-4-yl)ethoxy)acetic acid, TFA salt;
- 15 2-(2-(1-(3-(3-methoxyphenoxy)phenyl)-2-oxabicyclo[2.2.2]octan-4-yl)ethoxy)acetic acid;
- 2-(2-(1-(3-fluoro-5-phenoxyphenyl)-2-oxabicyclo[2.2.2]octan-4-yl)ethoxy)acetic acid;
- 2-(2-(1-(3-cyclopentenyl)phenyl)-2-oxabicyclo[2.2.2]octan-4-yl)ethoxy)acetic acid;
- 20 acid;
- 5-(1-(3-phenoxyphenyl)-2-oxabicyclo[2.2.2]octan-4-yl)-*N*-(phenylsulfonyl)pentanamide;
- N*-(methylsulfonyl)-5-(1-(3-phenoxyphenyl)-2-oxabicyclo[2.2.2]octan-4-yl)pentanamide;
- 25 2-(2-(1-(3-phenoxyphenyl)-2-oxabicyclo[2.2.2]octan-4-yl)acetamido)acetic acid;
- 2-((1-(3-phenoxyphenyl)-2-oxabicyclo[2.2.2]octan-4-yl)methylcarbamoxyloxy)acetic acid;
- 3-((1-(3-phenoxyphenyl)-2-oxabicyclo[2.2.2]octan-4-yl)methylsulfonyl)propanoic acid;
- 30 3-((4-(3-phenoxyphenyl)-2-oxabicyclo[2.2.2]octan-1-yl)methoxy)propanoic acid;

2-(2-(4-(3-phenoxyphenyl)-2-oxabicyclo[2.2.2]octan-1-yl)ethoxy)acetic acid;
 cis-2-(2-(1-(3-phenoxyphenyl)-2-oxabicyclo[2.2.2]octan-4-
 yl)ethyl)cyclopropanecarboxylic acid (racemic);
 3-methoxy-5-(1-(3-phenoxyphenyl)-2-oxabicyclo[2.2.2]octan-4-yl)pentanoic
 5 acid;
 (E)-5-(1-(3-phenoxyphenyl)-2-oxabicyclo[2.2.2]octan-4-yl)pent-3-enoic acid;
 (Z)-5-(1-(3-phenoxyphenyl)-2-oxabicyclo[2.2.2]octan-4-yl)pent-2-enoic acid;
 2-(2-(1-(3-fluoro-5-isobutoxyphenyl)-2-oxabicyclo[2.2.2]octan-4-yl)ethoxy)acetic
 acid;
 10 2-(2-(1-(2-phenoxyphenyl)-2-oxabicyclo[2.2.2]octan-4-yl)ethoxy)acetic acid;
 2-(2-(1-(3-(phenylthio)phenyl)-2-oxabicyclo[2.2.2]octan-4-yl)ethoxy)acetic acid;
 2-(2-(1-(3-(4-fluorophenoxy)phenyl)-2-oxabicyclo[2.2.2]octan-4-yl)ethoxy)acetic
 acid;
 15 2-(2-(1-(3-(4-chlorophenoxy)phenyl)-2-oxabicyclo[2.2.2]octan-4-yl)ethoxy)acetic
 acid;
 2-(2-(1-(3-(p-tolyloxy)phenyl)-2-oxabicyclo[2.2.2]octan-4-yl)ethoxy)acetic acid;
 2-(2-(1-(3-(4-methoxyphenoxy)phenyl)-2-oxabicyclo[2.2.2]octan-4-
 yl)ethoxy)acetic acid;
 2-(2-(1-(3-(m-tolyloxy)phenyl)-2-oxabicyclo[2.2.2]octan-4-yl)ethoxy)acetic acid;
 20 2-(2-(1-(3-(3-chlorophenoxy)phenyl)-2-oxabicyclo[2.2.2]octan-4-yl)ethoxy)acetic
 acid;
 2-(2-(1-(3-(3-fluorophenoxy)phenyl)-2-oxabicyclo[2.2.2]octan-4-yl)ethoxy)acetic
 acid;
 2-(2-(1-(3-(3-cyanophenoxy)phenyl)-2-oxabicyclo[2.2.2]octan-4-yl)ethoxy)acetic
 25 acid;
 2-(2-(1-(3-(trifluoromethylsulfonyloxy)phenyl)-2-oxabicyclo[2.2.2]octan-4-
 yl)ethoxy)acetic acid;
 2-(2-(1-(3-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl)-2-oxabicyclo[2.2.2]octan-4-
 yl)ethoxy)acetic acid;

- 2-(2-(1-(3-(trifluoromethyl)phenyl)-2-oxabicyclo[2.2.2]octan-4-yl)ethoxy)acetic acid;
- 2-(2-(1-(3-benzylphenyl)-2-oxabicyclo[2.2.2]octan-4-yl)ethoxy)acetic acid;
- 2-(2-(1-(3-(cyclobutylmethoxy)phenyl)-2-oxabicyclo[2.2.2]octan-4-yl)ethoxy)acetic acid;
- 5 2-(2-(1-(3-(cyclohexylmethoxy)phenyl)-2-oxabicyclo[2.2.2]octan-4-yl)ethoxy)acetic acid;
- 2-(2-(1-(3-(pentan-2-yloxy)phenyl)-2-oxabicyclo[2.2.2]octan-4-yl)ethoxy)acetic acid (racemate);
- 10 2-(2-(1-(3-fluoro-5-(2,2,2-trifluoroethoxy)phenyl)-2-oxabicyclo[2.2.2]octan-4-yl)ethoxy)acetic acid;
- 2-(2-(1-(3-fluoro-5-(3-fluorophenoxy)phenyl)-2-oxabicyclo[2.2.2]octan-4-yl)ethoxy)acetic acid;
- 4-(1-(3-phenoxyphenyl)-2-oxabicyclo[2.2.2]octan-4-yl)butane-1,2-diol;
- 15 4-(1-(3-phenoxyphenyl)-2-oxabicyclo[2.2.2]octan-4-yl)butan-1-ol;
- 5-(1-(3-phenoxyphenyl)-2-oxabicyclo[2.2.2]octan-4-yl)pentane-1,2-diol;
- S-5-(1-(3-phenoxyphenyl)-2-oxabicyclo[2.2.2]octan-4-yl)pentane-1,2-diol ;
- R-5-(1-(3-phenoxyphenyl)-2-oxabicyclo[2.2.2]octan-4-yl)pentane-1,2-diol;
- 2-(2-(1-(3-(tetrahydro-2H-pyran-2-yloxy)phenyl)-2-oxabicyclo[2.2.2]octan-4-yl)ethyl)cyclopropanecarboxylic acid;
- 20 N-((1H-1,2,4-triazol-5-yl)methyl)-2-(2-(1-(3-phenoxyphenyl)-2-oxabicyclo[2.2.2]octan-4-yl)ethyl)cyclopropanecarboxamide;
- 2-(2-(1-(3-fluoro-5-phenoxyphenyl)-2-oxabicyclo[2.2.2]octan-4-yl)ethyl)cyclopropanecarboxylic acid;
- 25 2-(2-(1-(3-fluoro-5-(3-fluorophenoxy)phenyl)-2-oxabicyclo[2.2.2]octan-4-yl)ethyl)cyclopropanecarboxylic acid;
- 2-(2-(1-(3-(3-fluorophenoxy)phenyl)-2-oxabicyclo[2.2.2]octan-4-yl)ethyl)cyclopropanecarboxylic acid;
- 2-(2-(1-(3-isobutoxyphenyl)-2-oxabicyclo[2.2.2]octan-4-yl)ethyl)cyclopropanecarboxylic acid (single enantiomer);
- 30

- 2-(2-(1-(3-(3-methoxyphenoxy)phenyl)-2-oxabicyclo[2.2.2]octan-4-yl)ethyl)cyclopropanecarboxylic acid (single enantiomer);
- N-((1H-1,2,4-triazol-5-yl)methyl)-2-(2-(1-(3-phenoxyphenyl)-2-oxabicyclo[2.2.2]octan-4-yl)ethyl)cyclopropanecarboxamide;
- 5 N-ethyl-2-(2-(1-(3-phenoxyphenyl)-2-oxabicyclo[2.2.2]octan-4-yl)ethyl)cyclopropanecarboxamide;
- 2-(2-(1-(3-(3-hydroxyphenoxy)phenyl)-2-oxabicyclo[2.2.2]octan-4-yl)ethyl)cyclopropanecarboxylic acid;
- (1R,2R)-2-(2-(1-(3-(4-methoxyphenoxy)phenyl)-2-oxabicyclo[2.2.2]octan-4-yl)ethyl)cyclopropanecarboxylic acid;
- 10 (1R,2R)-2-(2-(1-(3-(3,5-difluorophenoxy)phenyl)-2-oxabicyclo[2.2.2]octan-4-yl)ethyl)cyclopropanecarboxylic acid;
- (1R,2R)-2-(2-(1-(3-(3,4-difluorophenoxy)phenyl)-2-oxabicyclo[2.2.2]octan-4-yl)ethyl)cyclopropanecarboxylic acid;
- 15 (1R,2R)-2-(2-(1-(3-(4-hydroxyphenoxy)phenyl)-2-oxabicyclo[2.2.2]octan-4-yl)ethyl)cyclopropanecarboxylic acid;
- 2-(2-(1-(3-(3,4-difluorophenoxy)phenyl)-2-oxabicyclo[2.2.2]octan-4-yl)ethoxy)acetic acid;
- 2-(2-(1-(3-(3,5-difluorophenoxy)phenyl)-2-oxabicyclo[2.2.2]octan-4-yl)ethoxy)acetic acid;
- 20 2-(2-(1-(3-(3-fluoro-4-methylphenoxy)phenyl)-2-oxabicyclo[2.2.2]octan-4-yl)ethoxy)acetic acid;
- 2-(2-(1-(3-(4-fluoro-3-methylphenoxy)phenyl)-2-oxabicyclo[2.2.2]octan-4-yl)ethoxy)acetic acid;
- 25 2-(2-(1-(3-(3,4-difluorophenoxy)-5-fluorophenyl)-2-oxabicyclo[2.2.2]octan-4-yl)ethoxy)acetic acid;
- 2-(2-(1-(3-fluoro-5-(3-fluoro-4-methylphenoxy)phenyl)-2-oxabicyclo[2.2.2]octan-4-yl)ethoxy)acetic acid;
- 2-(2-(1-(3-fluoro-5-(4-fluoro-3-methylphenoxy)phenyl)-2-oxabicyclo[2.2.2]octan-4-yl)ethoxy)acetic acid;
- 30

- 2-(2-(1-(3-fluoro-5-(3-methoxyphenoxy)phenyl)-2-oxabicyclo[2.2.2]octan-4-yl)ethoxy)acetic acid;
- 2-(2-(1-(3-fluoro-5-(p-tolyloxy)phenyl)-2-oxabicyclo[2.2.2]octan-4-yl)ethoxy)acetic acid;
- 5 2-(2-(1-(3-fluoro-5-(3-fluoro-5-methoxyphenoxy)phenyl)-2-oxabicyclo[2.2.2]octan-4-yl)ethoxy)acetic acid;
- 2-(2-(1-(3-fluoro-5-(4-fluorophenoxy)phenyl)-2-oxabicyclo[2.2.2]octan-4-yl)ethoxy)acetic acid;
- 2-(2-(1-(3-fluoro-5-(4-fluoro-3-methoxyphenoxy)phenyl)-2-oxabicyclo[2.2.2]octan-4-yl)ethoxy)acetic acid;
- 10 2-(2-(1-(4-fluoro-3-phenoxyphenyl)-2-oxabicyclo[2.2.2]octan-4-yl)ethoxy)acetic acid;
- 2-(2-(1-(4-fluoro-3-(4-fluorophenoxy)phenyl)-2-oxabicyclo[2.2.2]octan-4-yl)ethoxy)acetic acid;
- 15 2-(2-(1-(4-fluoro-3-(3-fluoro-4-methylphenoxy)phenyl)-2-oxabicyclo[2.2.2]octan-4-yl)ethoxy)acetic acid;
- 2-(2-(1-(3-methoxy-5-phenoxyphenyl)-2-oxabicyclo[2.2.2]octan-4-yl)ethoxy)acetic acid;
- 2-(2-(1-(3-(3,4-difluorophenoxy)-5-methoxyphenyl)-2-oxabicyclo[2.2.2]octan-4-yl)ethoxy)acetic acid;
- 20 2-(2-(1-(3-(4-fluorophenoxy)-5-methoxyphenyl)-2-oxabicyclo[2.2.2]octan-4-yl)ethoxy)acetic acid;
- 2-(2-(1-(3-(3-fluoro-4-methylphenoxy)-5-methoxyphenyl)-2-oxabicyclo[2.2.2]octan-4-yl)ethoxy)acetic acid;
- 25 2-(2-(1-(3-fluoro-5-(3-fluoro-4-methylphenoxy)phenyl)-2-oxabicyclo[2.2.2]octan-4-yl)ethoxy)-N-hydroxyacetamide;
- 2-(2-(1-(3,4-difluoro-5-(4-fluorophenoxy)phenyl)-2-oxabicyclo[2.2.2]octan-4-yl)ethoxy)acetic acid;
- 2-(((1-(3-phenoxyphenyl)-2-oxabicyclo[2.2.2]octan-4-yl)oxy)methyl)cyclopropanecarboxylic acid;
- 30

- trans-2-(((1-(3-phenoxyphenyl)-2-oxabicyclo[2.2.2]octan-4-yl)methoxy)methyl)cyclopropanecarboxylic acid;
- 2-(2-(4-(3-(3-fluoro-4-methoxyphenoxy)phenyl)-2-oxabicyclo[2.2.2]octan-1-yl)ethoxy)acetic acid;
- 5 2-(2-(4-(3-(3-fluoro-4-methoxyphenoxy)phenyl)-2-oxabicyclo[2.2.2]octan-1-yl)ethoxy)acetic acid;
- 2-(2-(4-(3-(3-fluoro-4-methylphenoxy)phenyl)-2-oxabicyclo[2.2.2]octan-1-yl)ethoxy)acetic acid;
- 10 2-(2-(4-(3-(3-methoxyphenoxy)phenyl)-2-oxabicyclo[2.2.2]octan-1-yl)ethoxy)acetic acid;
- 2-(2-(4-(3-(4-fluoro-3-methylphenoxy)phenyl)-2-oxabicyclo[2.2.2]octan-1-yl)ethoxy)acetic acid;
- 2-(2-(4-(3-(pyridin-3-yloxy)phenyl)-2-oxabicyclo[2.2.2]octan-1-yl)ethoxy)acetic acid;
- 15 2-(2-(4-(3-(4-fluorophenoxy)phenyl)-2-oxabicyclo[2.2.2]octan-1-yl)ethoxy)acetic acid;
- 2-(2-(4-(3-(p-tolyloxy)phenyl)-2-oxabicyclo[2.2.2]octan-1-yl)ethoxy)acetic acid;
- 2-(2-(4-(3-(3-cyanophenoxy)phenyl)-2-oxabicyclo[2.2.2]octan-1-yl)ethoxy)acetic acid;
- 20 2-(2-(4-(3-fluoro-5-(3-fluoro-4-methylphenoxy)phenyl)-2-oxabicyclo[2.2.2]octan-1-yl)ethoxy)acetic acid;
- 2-(2-(4-(3-(pyridin-2-yloxy)phenyl)-2-oxabicyclo[2.2.2]octan-1-yl)ethoxy)acetic acid;
- 2-(3-(4-(3-phenoxyphenyl)-2-oxabicyclo[2.2.2]octan-1-yl)propoxy)acetic acid;
- 25 2-(2-(4-(3-(cyclohexyloxy)phenyl)-2-oxabicyclo[2.2.2]octan-1-yl)ethoxy)acetic acid;
- 2-(2-(4-(4-fluoro-3-(3-fluoro-4-methylphenoxy)phenyl)-2-oxabicyclo[2.2.2]octan-1-yl)ethoxy)acetic acid;
- 2-(2-(4-(3-(3,4-dimethylphenoxy)-4-fluorophenyl)-2-oxabicyclo[2.2.2]octan-1-yl)ethoxy)acetic acid;
- 30

2-(2-(4-(3-(4-cyano-3-methylphenoxy)-4-fluorophenyl)-2-oxabicyclo[2.2.2]octan-1-yl)ethoxy)acetic acid;

2-(2-(1-(3-(6-methylpyridin-3-yloxy)phenyl)-2-oxabicyclo[2.2.2]octan-4-yl)ethoxy)acetic acid;

5 2-(2-(1-(6-(3,4-difluorophenoxy)pyridin-2-yl)-2-oxabicyclo[2.2.2]octan-4-yl)ethoxy)acetic acid;

2-(2-(1-(3-(3-hydroxyphenoxy)phenyl)-2-oxabicyclo[2.2.2]octan-4-yl)ethoxy)acetic acid;

10 (1R,2R)-2-(2-(1-(3-(3-ethylphenoxy)phenyl)-2-oxabicyclo[2.2.2]octan-4-yl)ethyl)cyclopropanecarboxylic acid;

2-(2-(1-(3-(3-ethylphenoxy)phenyl)-2-oxabicyclo[2.2.2]octan-4-yl)ethoxy)acetic acid; and

2-(3-(1-(3-phenoxyphenyl)-2-oxabicyclo[2.2.2]octan-4-yl)propyl)cyclopropanecarboxylic acid.

15

8. A pharmaceutical composition, comprising a pharmaceutically acceptable carrier and a compound of any one of claims 1 to 7, or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof.

20 9. The pharmaceutical composition according to claim 8, further comprising one or more other suitable therapeutic agents useful in the treatment of the aforementioned disorders including: anti-diabetic agents, anti-hyperglycemic agents, anti-hyperinsulinemic agents, anti-retinopathic agents, anti-neuropathic agents, anti-nephropathic agents, anti-atherosclerotic agents, anti-ischemic agents,
25 anti-hypertensive agents, anti-obesity agents, anti-dyslipidemic agents, anti-hyperlipidemic agents, anti-hypertriglyceridemic agents, anti-hypercholesterolemic agents, anti-pancreatitis agents, lipid lowering agents, anorectic agents and appetite suppressants.

10. The pharmaceutical composition according to claim 8, further comprising one or more other suitable therapeutic agents selected from: a dipeptidyl peptidase-IV inhibitor, a sodium-glucose transporter-2 inhibitor and a 11b-HSD-1 inhibitor.

5 11. The compound of any one of claims 1 to 7 for use in treating diabetes, hyperglycemia, impaired glucose tolerance, gestational diabetes, insulin resistance, hyperinsulinemia, retinopathy, neuropathy, nephropathy, diabetic kidney disease, acute kidney injury, cardiorenal syndrome, delayed wound healing, atherosclerosis and its sequelae, abnormal heart function, congestive heart failure, myocardial ischemia, stroke,
10 Metabolic Syndrome, hypertension, obesity, fatty liver disease, dislipidemia, dyslipidemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, low high-density lipoprotein (HDL), high low-density lipoprotein (LDL), lipid disorders and liver diseases such as NASH (Non-Alcoholic SteatoHepatitis), NAFLD (Non-Alcoholic Fatty Liver Disease) and liver cirrhosis.

15 12. A compound for use according to claim 11, wherein the compound of any one of of claims 1 to 7 is used simultaneously, separately or sequentially with one or more additional therapeutic agents.

20